The privately-owned company has six clinical-stage compounds in its pipeline, acquired through partnerships with Novartis, Roche and Syngenta. Two of these compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, such as anxiety and Parkinson's disease. In addition to developing products, Synosia Therapeutics also offers clinical development program and research services.